A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
Compass Therapeutics
GlaxoSmithKline
Hospital Universitari de Bellvitge
Qilu Pharmaceutical Co., Ltd.
Convalife (Shanghai) Co., Ltd.
Rutgers, The State University of New Jersey
Kaiser Permanente
Ellele Health
Mayo Clinic
University Hospital, Strasbourg, France
Cogent Biosciences, Inc.
Asan Medical Center
Peking University People's Hospital
European Institute of Oncology
UNC Lineberger Comprehensive Cancer Center
Women's Hospital School Of Medicine Zhejiang University
Taipei Veterans General Hospital, Taiwan
European Institute of Oncology
Natera, Inc.
Medical College of Wisconsin
UNC Lineberger Comprehensive Cancer Center
Second Life Therapeutics
Peking Union Medical College Hospital
National Cancer Institute, Naples
Rocky Vista University, LLC
Assiut University
University of Rochester
Sun Yat-sen University
Centre Leon Berard
University College, London
GlaxoSmithKline
Peking University People's Hospital
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Tongji Hospital
University Health Network, Toronto
Hospital Italiano de Buenos Aires
Cycle Therapeutics Ltd
Peking University People's Hospital
University of South Florida
Istanbul University
Erasmus Medical Center
Universidade Federal de Pernambuco
Akdeniz University
Peking Union Medical College Hospital
Peking Union Medical College Hospital
Region Stockholm
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Fudan University
BioMimetix JV, LLC